Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.

about

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.

P2860

Q36192072-6DC66260-65EB-495D-BC8C-E3FCCAEC7A6B

P2860

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.

Item

http://www.wikidata.org/entity/Q53401668

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Disposition and metabolism of ...... ZD4054) in healthy volunteers.

@en

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan

@nl

type

Item

label

Disposition and metabolism of ...... ZD4054) in healthy volunteers.

@en

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan

@nl

prefLabel

Disposition and metabolism of ...... ZD4054) in healthy volunteers.

@en

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan

@nl

P1476

Disposition and metabolism of ...... ZD4054) in healthy volunteers.

@en

P2093

Alison S J Kenyon

http://www.w3.org/2001/XMLSchema#string

Eva M Lenz

http://www.w3.org/2001/XMLSchema#string

Helen Swaisland

http://www.w3.org/2001/XMLSchema#string

Jacqueline A Clarkson-Jones

http://www.w3.org/2001/XMLSchema#string

John Kemp

http://www.w3.org/2001/XMLSchema#string

Stuart D Oliver

http://www.w3.org/2001/XMLSchema#string

P2860

Endothelin receptors as novel targets in tumor therapy

The endothelin axis: emerging role in cancer

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.

Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.

An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.

ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers.

P304

363-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/00498254.2011.624204

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22014279

http://www.w3.org/2001/XMLSchema#string

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.

about

P2860

P2860

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698